Navigation Links
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Date:4/6/2009

Company to Submit a Supplemental New Drug Application to Expand the NUVIGIL(R) Label

FRAZER, Pa., April 6 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a phase three clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as a treatment for excessive sleepiness associated with jet lag disorder. Based on these findings, Cephalon(R) will file a supplemental New Drug Application with the U.S. Food and Drug Administration to expand the indications for NUVIGIL during the third quarter of this year.

The efficacy and safety of NUVIGIL as a potential treatment for acute excessive sleepiness associated with jet lag disorder were evaluated over the course of three days in a randomized, double-blind, placebo-controlled study of 427 healthy adults who had experienced jet lag symptoms during the previous five years. Participants in the study traveled eastbound from the United States to France where they were then examined at a sleep facility. Clinical efficacy was evaluated using two primary endpoints: an objective assessment -- the Multiple Sleep Latency Test (MSLT), and a subjective assessment -- the Patient Global Impression of Severity (PGI-S). Patients taking NUVIGIL (150 mg) showed a statistically significant improvement over placebo as measured by the MSLT [p<0.0001] and the PGI-S [p<0.05]. The results of this study will be submitted for presentation at a future medical meeting.

"After flying the subjects over the Atlantic, we objectively evaluated those receiving placebo versus those receiving NUVIGIL," said Dr. Lesley Russell, Chief Medical Officer and Executive Vice President at Cephalon. "We discovered that those on placebo were as excessivel
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
4. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
5. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
8. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
9. Schering-Plough Announces Results of the Early ACS Trial
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 The National Association of Managed ... released the NAMCP Medical Technologies Dossier Template © ... © , which provide medical directors and manufacturers ... devices or diagnostics that accounts for evidence-based development ... technology types (instead of having to attempt to ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... product to receive formal designation as a "Promising Innovative ... Scheme" (EAMS) launched in the UK in April 2014. ... process for early access approval under the EAMS.  ...
Breaking Medicine Technology:NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5
(Date:9/16/2014)... 2014 Marybeth Cale, owner of Cale ... of Manhattan in the small village of Rhinebeck, New York, ... business. Cale, a mompreneur, has expanded the business to incorporate ... people to maximize potential. Those services will include group trainings ... one-on-one life coaching for clients all over the country. ...
(Date:9/16/2014)... 2014 Operation Smile was founded “on the ... a facial deformity.” To spread their message and mission, the ... at the Beverly Wilshire Hotel in Beverly Hills, California. The ... whose lives have been forever transformed by the efforts of ... with Operation Smile,” said Lynda Erkiletian, Executive Director of The ...
(Date:9/16/2014)... 2014 On Friday, September 12, ... product extensions, an accompanying mobile application, the grand-opening ... tools for their sales force, and their sponsorship ... 5th annual national convention, Rise to Enterprise 2014 ... the Hyatt Regency Orange County was treated to ...
(Date:9/16/2014)... Silver Spring, Md. (PRWEB) September 16, 2014 ... The Road , Free Education Forum for PH Patients and ... Pulmonary Hypertension Association – the country’s leading pulmonary hypertension ... pulmonary hypertension (PH) – a disease of the lungs that ... right heart failure. Without treatment, mean survivability is only 2.8 ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, ... spot human papillomavirus (HPV), which is linked to the risk ... shows that testing urine for HPV has good accuracy when ... said lead researcher Dr. Neha Pathak. She is a resident ... University of London, England. The test could be done ...
Breaking Medicine News(10 mins):Health News:Mompreneur Marybeth Cale of Cale Communications Announces Launch Of Life Coaching And Workshop Business 2Health News:James & Paula Coburn Foundation to Host the 2014 Smile Gala, Presented by Operation Smile 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 2Health News:New Products Announced at Jusuru International’s R2E14 National Convention 3Health News:New Products Announced at Jusuru International’s R2E14 National Convention 4Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Urine Test for HPV Works Well, Analysis Finds 2
... driving challenges this time of year, safety group says ... brings plenty of road hazards and challenges: wet leaves, lumbering ... year, September had the second-highest number of deaths per mile ... per 100 million vehicle miles, according to the National Safety ...
... ... year, 35 to 50 million Americans become infected with the flu (influenza). On average, the ... TX is taking steps to combat these preventable deaths by offering free flu shots . ... Plano, TX (Vocus) September 12, 2009 ...
... ... Pappagallo, MD, Present Partnering Primary Care Physicians with Pain Specialists , ... Las Vegas, NV (PRWEB) September 12, 2009 -- PAINWeek® ... CPE, and Dr. Marco Pappagallo, MD, teaching a Master Class that addressed the need for ...
... , , , ... leading provider of kidney care services for those diagnosed with chronic kidney ... series of 5K events raising funds and awareness of CKD across the ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) , , ...
... The Johns Hopkins Bloomberg School of Public Health has ... Research Program (OETRP) of the U.S. Department of Defense ... Bloomberg School will serve as the coordinating center for ... civilian trauma centers working together with several major military ...
... CHICAGO, Sept. 11 Schofield Media Group has promoted Brian ... U.S. and European operations consisting of five divisions and more than ... in 2006 as executive president, and in 2008 was made group ... made and continues to make a great contribution to the company," ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:Need for Pain and Palliative Care Mentorship Addressed at PAINweek 2009 2Health News:DaVita Launches Nationwide Series of Kidney Awareness Run/Walks 2Health News:JHSPH to lead extremity trauma clinical research consortium 2Health News:JHSPH to lead extremity trauma clinical research consortium 3
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
Medicine Products: